CA2236888A1 - Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites - Google Patents

Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites

Info

Publication number
CA2236888A1
CA2236888A1 CA002236888A CA2236888A CA2236888A1 CA 2236888 A1 CA2236888 A1 CA 2236888A1 CA 002236888 A CA002236888 A CA 002236888A CA 2236888 A CA2236888 A CA 2236888A CA 2236888 A1 CA2236888 A1 CA 2236888A1
Authority
CA
Canada
Prior art keywords
parasites
tumors
viruses
medicament
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002236888A
Other languages
French (fr)
Other versions
CA2236888C (en
Inventor
Joachim Robert Kalden
Martin Herrmann
Reinhard Voll
Wolf Maximilian Bertling
Klaus Von Der Mark
Otmar Zoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2236888A1 publication Critical patent/CA2236888A1/en
Application granted granted Critical
Publication of CA2236888C publication Critical patent/CA2236888C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites, where an active compound selected from the following group is contained for influencing the phosphatidlyserine-dependent [sic] phagocytosis: annexin, annexin antibodies, annexin ligands or phosphatidlyserine [sic].
CA002236888A 1995-11-06 1996-11-04 Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites Expired - Fee Related CA2236888C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19541284.2 1995-11-06
DE19541284A DE19541284C2 (en) 1995-11-06 1995-11-06 Immunomodulation method
PCT/EP1996/004791 WO1997017084A1 (en) 1995-11-06 1996-11-04 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites

Publications (2)

Publication Number Publication Date
CA2236888A1 true CA2236888A1 (en) 1997-05-15
CA2236888C CA2236888C (en) 2009-10-13

Family

ID=7776729

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002236888A Expired - Fee Related CA2236888C (en) 1995-11-06 1996-11-04 Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites

Country Status (7)

Country Link
EP (2) EP1356818A3 (en)
JP (1) JP2000500124A (en)
AT (1) ATE245995T1 (en)
CA (1) CA2236888C (en)
DE (2) DE19541284C2 (en)
ES (1) ES2205065T3 (en)
WO (1) WO1997017084A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19541284C2 (en) * 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Immunomodulation method
US7262167B2 (en) 1995-11-06 2007-08-28 Exibona Ltd. Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
DE69904831T2 (en) 1998-07-13 2003-11-06 Univ Texas CANCER TREATMENT WITH AMINOPHOSPHOLIPIDE BINDING THERAPEUTIC CONJUGATES
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
BR9911882A (en) 1998-07-13 2005-02-15 Univ Texas Cancer treatment process employing aminophospholipid antibodies
JP2003501478A (en) * 1999-06-09 2003-01-14 イ・デ・エム・イミュノ−デジネ・モレキュル New molecular conjugates exhibiting high affinity binding for monocyte-derived cells and their use in therapy
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
ATE359807T1 (en) 2001-02-21 2007-05-15 Surromed Inc MODIFIED ANNEXIN PROTEINS AND PREVENTION AND TREATMENT OF THROMBOSIS
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
WO2002082044A2 (en) * 2001-04-03 2002-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
DE10145254A1 (en) * 2001-09-13 2003-04-10 November Ag Molekulare Medizin Use of a protein in the manufacture of a medicament for stimulating an inflammatory cellular immune response
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
DE10302422A1 (en) * 2003-01-21 2004-07-29 Responsif Gmbh Composition for treating cancer, particularly carcinoma of the breast, and that reduces tumor mass in only a few days, comprises annexin V and a cytokine, such as an interleukin or granulocyte-macrophage colony-stimulating factor
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
EP1670510A1 (en) * 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
DE102004046540A1 (en) * 2004-09-21 2006-04-06 Eberhard-Karls-Universität Tübingen Universitätsklinikum Annexin modulation and infection resistance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605561A4 (en) * 1991-09-23 1995-04-12 Gen Hospital Corp Annexin xi.
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
DE19541284C2 (en) * 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Immunomodulation method

Also Published As

Publication number Publication date
DE59610633D1 (en) 2003-09-04
EP0859628B1 (en) 2003-07-30
JP2000500124A (en) 2000-01-11
EP0859628B9 (en) 2004-03-03
ATE245995T1 (en) 2003-08-15
DE19541284A1 (en) 1996-05-30
WO1997017084A1 (en) 1997-05-15
EP1356818A2 (en) 2003-10-29
DE19541284C2 (en) 1998-09-24
ES2205065T3 (en) 2004-05-01
EP0859628A1 (en) 1998-08-26
EP1356818A3 (en) 2003-12-10
CA2236888C (en) 2009-10-13

Similar Documents

Publication Publication Date Title
CA2236888A1 (en) Medicament, in particular for modulation of the immune response in the control of viruses, tumors, bacteria and parasites
CA2172376A1 (en) Antibodies to cd40
AU4597596A (en) Prevention of protein aggregation
EP0610445A4 (en) Compositions comprising a bactericidal/permeability increasing protein and a lipid carrier, methods of making same, and uses thereof.
CA2115348A1 (en) Process for the production of pharmaceutical preparations containing human protein for infusion or injection purposes
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2105552A1 (en) Soluble ligands for cd40
EP0644946A4 (en) Vector particles resistant to inactivation by human serum.
CA2381770A1 (en) Human ctla-4 antibodies and their uses
CA2154424A1 (en) 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect
CA2178262A1 (en) Process for the preparation of microcapsule compositions
AU6818196A (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
CA2182289A1 (en) Immuno-stimulatory monoclonal antibodies
AU609981B2 (en) Oil-in-water pesticidal emulsion, process for application
CA2181165A1 (en) Anti-fungal methods and materials
AU2967595A (en) Anti-protozoan methods and materials
AU672153B2 (en) Cotton harvester
CA2213798A1 (en) Method for stimulating an immune response
CA2173611A1 (en) Method of treating depressed reticuloendothelial system function
AU5693296A (en) Pectic preparations used as medicament carriers
AU6449390A (en) Adaptive braking system default activated proportioning valve
CA2238278A1 (en) Antigenic protein originating in malassezia
AU4729396A (en) Process for the preparation of 1,2-benzisothiazolin-3-ones
AU2643495A (en) Assay for pathogenicity of anti-dna antibodies
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed